New technology for the diagnostic of Ankle Brachial Index

HealthWorks announces a new technology for the diagnosis of peripheral arterial disease. The SCVL will make the measurement of ABI accessible to all doctors.

London, 21 January 2010

A novel technology developed by HealthWorks Global is now listed on the BHS (British Hypertension Society) website as the only device that measures ABI and cardiac output validated for clinical use. The HealthWorks SCVL (Screening CardioVascular Lab) is a USB-driven blood pressure monitoring system that measures or calculates not only blood pressure, but also Ankle Brachial Index (ABI), Pulse Pressure (PP), Mean Arterial Pressure (MAP), Cardiac Output (amount of blood pumped by the heart per minute) and Stroke Volume (amount of blood pumped by the heart per contraction). The SCVL technology makes it possible to take a precise, reliable and quick measurement of all these parameters in less than 3 minutes. This new device also integrates a full patient risk analysis based on the Framingham Risk Scores.

The SCVL was recently validated against a Doppler in France and Belgium in two independent clinical studies where the SCVL scored a higher sensitivity than the Doppler in the measurement of Ankle Brachial Index measurements and in the detection of peripheral arterial diseases. The monitoring system uses measuring devices that are placed on the upper arm and on the ankle. The SCVL is battery-less and is driven by a computer that displays real-time pulse waves and superimposes them to measure ABI. The innovations provided by the SCVL technology match all recommendations made by the medical community and are in line with an international trend that recognizes the importance of ABI as a valuable measurement of arterial health.

A technology developed for medical use

Ankle-Brachial is an essential component for the screening, diagnosis and management of peripheral arterial disease. The measurement of ABI provides a simple, rapid and effective method for the evaluation of the distal perfusion of lower and upper limbs. ABI is an excellent marker of peripheral arterial disease, even prior to the occurrence of functional symptoms. Beyond the diagnosis of peripheral arterial disease, ABI is nowadays known as a marker of atherosclerosis and as a cardiovascular marker. According to Dr Olaf Diegel, team leader for the software development “historically, ABI is measured using a Doppler Test, which is a time-consuming and difficult measurement procedure, rarely undertaken by the generalist because of time and training constraints. The SCVL aims to facilitate the measurement of ABI and other indicators of peripheral arterial disease so that these tests can be introduced as part of the every day routine of the generalist doctor, so that preventative screening of arterial disease can be made”.

Observing the recommendations of the medical community

Clinical validation is an essential part of the development of the HealthWorks business as a provider of managed healthcare tools. This is line with HealthWorks’ company policies and reflects the deep concern of HealthWorks for the elements, which form part of their business vision. HealthWorks is also taking an active role in managed healthcare by working with doctors to develop systems where medical practitioners take an active role in managing their patients’ overall health by monitoring new parameters so that they can better understand their bodies.

End, 21 January 2010…

HealthWorks, a recognized and validated company

By basing the core of its business not only on sales but also on service, HealthWorks is helping people by empowering them to manage their diseases and to take responsibility for their health. HealthWorks is establishing itself as one of the most progressive medical companies providing managed healthcare worldwide. For more information on HealthWorks, please logon to www.healthworksglobal.net.

For more information, contact:
Name: Uwe DIEGEL
President, HealthWorks France
6 rue de Castellane, 75008, Paris, France
Direct line: +33 (0)6 76 31 29 93
Mail: udiegel@diegelhealthworks.com

This release was published on openPR.